pt141 nausea Ozempic for Weight Loss: Side Effects, Vs. Wegovy, and More GLP-1 Drugs for Weight Loss:

Preliminary research suggests that patients with ME/CFS have lower MOTS-c expression and signs of impaired mitochondrial fusion

Orthop J Sports Med

Refreshing Citrus Scent

3 min read The GLP-1 landscape changed on 1 April 2026, when the FDA approved Eli Lilly's orforglipron under the brand name Foundayo as the first non-peptide, small-molecule GLP-1 receptor agonist (GLP-1RA) anywhere in the world

The drug is currently in phase 3 trials for obesity and Type 2 diabetes

A common approach to study bacterial motility is fluorescent labeling, which allows detection of individual bacterial cells in a population or in host tissues